President's Message
News Release
OrphanPacific Obtains Marketing Approval in Japan for Leniolisib (Joenja®) for the Treatment of APDS for adults and pediatric patients 4 years of age and older
Notice of Marketing Authorization for “RAVICTI® Oral Liquid 1.1 g/mL” for Urea Cycle Disorders
Notice of Head Office Relocation (Change of Building)
Announcement Regarding the Designation of Glycerol Phenylbutyrate as an Orphan Drug
Announcement of Application for Approval of Glycerol Phenylbutyrate for the Treatment of Urea Cycle Disorder
